Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer
Aclaris Therapeutics has appointed Jesse Hall, M.D. as Chief Medical Officer, strengthening its leadership in immuno-inflammatory disease therapeutics. Dr. Hall brings extensive experience in clinical development, particularly in immunology and antibody development.
Dr. Hall's previous role was CMO at AltruBio, and he has held positions at notable companies including Sublimity Therapeutics, Ardea Biosciences (AstraZeneca), Amgen, and Abbott Labs. His track record includes work on successful monoclonal antibodies like HUMIRA and PROLIA.
As part of his employment package starting May 1, 2025, Dr. Hall will receive:
- 510,000 nonstatutory stock options
- 145,500 restricted stock units
These equity awards will vest over four years, with 25% vesting annually, subject to continued employment. The grants are part of Aclaris' 2024 Inducement Plan, designed for new employees under Nasdaq Rule 5635(c)(4).
Aclaris Therapeutics ha nominato Jesse Hall, M.D. come Chief Medical Officer, rafforzando la propria leadership nel settore delle terapie per le malattie immuno-infiammatorie. Il dottor Hall vanta una vasta esperienza nello sviluppo clinico, in particolare in immunologia e sviluppo di anticorpi.
In precedenza, il dottor Hall è stato CMO presso AltruBio e ha ricoperto ruoli in aziende di rilievo come Sublimity Therapeutics, Ardea Biosciences (AstraZeneca), Amgen e Abbott Labs. Tra i suoi successi figurano lo sviluppo di anticorpi monoclonali di successo come HUMIRA e PROLIA.
Come parte del suo pacchetto di assunzione a partire dal 1° maggio 2025, il dottor Hall riceverà:
- 510.000 opzioni azionarie non statutarie
- 145.500 unità azionarie vincolate
Questi premi azionari matureranno in quattro anni, con il 25% che matura ogni anno, subordinatamente alla continuazione dell’impiego. Le assegnazioni fanno parte del Piano di Incentivazione 2024 di Aclaris, creato per i nuovi dipendenti secondo la Regola Nasdaq 5635(c)(4).
Aclaris Therapeutics ha nombrado a Jesse Hall, M.D. como Director Médico, fortaleciendo su liderazgo en terapias para enfermedades inmuno-inflamatorias. El Dr. Hall aporta amplia experiencia en desarrollo clínico, especialmente en inmunología y desarrollo de anticuerpos.
Anteriormente, el Dr. Hall fue CMO en AltruBio y ha ocupado cargos en compañías destacadas como Sublimity Therapeutics, Ardea Biosciences (AstraZeneca), Amgen y Abbott Labs. Su trayectoria incluye el trabajo en anticuerpos monoclonales exitosos como HUMIRA y PROLIA.
Como parte de su paquete laboral a partir del 1 de mayo de 2025, el Dr. Hall recibirá:
- 510,000 opciones sobre acciones no estatutarias
- 145,500 unidades restringidas de acciones
Estos premios de capital se consolidarán durante cuatro años, con un 25% consolidándose anualmente, sujeto a la continuidad del empleo. Las asignaciones forman parte del Plan de Incentivos 2024 de Aclaris, diseñado para nuevos empleados bajo la Regla Nasdaq 5635(c)(4).
Aclaris Therapeutics가 Jesse Hall, M.D.를 최고 의료 책임자(CMO)로 임명하여 면역 염증 질환 치료제 분야에서의 리더십을 강화했습니다. Hall 박사는 임상 개발, 특히 면역학 및 항체 개발 분야에서 풍부한 경험을 갖추고 있습니다.
Hall 박사는 이전에 AltruBio에서 CMO로 근무했으며 Sublimity Therapeutics, Ardea Biosciences(AstraZeneca), Amgen, Abbott Labs 등 주요 회사에서 근무한 경력이 있습니다. 그는 HUMIRA와 PROLIA와 같은 성공적인 단클론 항체 개발에 참여한 바 있습니다.
2025년 5월 1일부터 시작되는 고용 패키지의 일환으로 Hall 박사는 다음을 받게 됩니다:
- 510,000 비법정 주식 매수 옵션
- 145,500 제한 주식 단위
이러한 주식 보상은 4년에 걸쳐 매년 25%씩 베스팅되며, 계속 고용 조건이 충족되어야 합니다. 이 보상은 Nasdaq 규칙 5635(c)(4)에 따른 신규 직원용 Aclaris의 2024년 유인 계획의 일부입니다.
Aclaris Therapeutics a nommé Jesse Hall, M.D. au poste de Chief Medical Officer, renforçant ainsi son leadership dans les traitements des maladies immuno-inflammatoires. Le Dr Hall apporte une vaste expérience en développement clinique, notamment en immunologie et en développement d’anticorps.
Auparavant, le Dr Hall était CMO chez AltruBio et a occupé des postes dans des entreprises renommées telles que Sublimity Therapeutics, Ardea Biosciences (AstraZeneca), Amgen et Abbott Labs. Son parcours inclut la participation à des anticorps monoclonaux à succès comme HUMIRA et PROLIA.
Dans le cadre de son contrat débutant le 1er mai 2025, le Dr Hall recevra :
- 510 000 options d’achat d’actions non statutaires
- 145 500 unités d’actions restreintes
Ces attributions d’actions seront acquises sur quatre ans, avec un vesting annuel de 25 %, sous réserve de la poursuite de l’emploi. Ces attributions font partie du Plan d’Incitation 2024 d’Aclaris, conçu pour les nouveaux employés conformément à la règle Nasdaq 5635(c)(4).
Aclaris Therapeutics hat Jesse Hall, M.D. zum Chief Medical Officer ernannt und damit seine Führungsposition im Bereich der Immun-entzündlichen Erkrankungen gestärkt. Dr. Hall bringt umfangreiche Erfahrung in der klinischen Entwicklung mit, insbesondere in Immunologie und Antikörperentwicklung.
Dr. Hall war zuvor CMO bei AltruBio und hatte Positionen bei namhaften Unternehmen wie Sublimity Therapeutics, Ardea Biosciences (AstraZeneca), Amgen und Abbott Labs inne. Zu seinen Erfolgen zählen die Entwicklung erfolgreicher monoklonaler Antikörper wie HUMIRA und PROLIA.
Im Rahmen seines Anstellungspakets ab dem 1. Mai 2025 erhält Dr. Hall:
- 510.000 nichtstatutarische Aktienoptionen
- 145.500 eingeschränkte Aktieneinheiten
Diese Aktienzuteilungen werden über vier Jahre mit einer jährlichen Vestingrate von 25 % gewährt, vorbehaltlich der Fortsetzung des Arbeitsverhältnisses. Die Zuteilungen sind Teil des Aclaris-Induzierungsplans 2024, der für neue Mitarbeiter gemäß Nasdaq-Regel 5635(c)(4) konzipiert ist.
- New CMO brings extensive experience in drug development and global regulatory filings
- Dr. Hall has direct experience with successful antibody therapeutics (HUMIRA, PROLIA)
- Company reports having ample cash resources for current goals
- Deep clinical pipeline with near-term milestones
- Significant equity compensation package (510,000 stock options and 145,500 RSUs) may lead to future dilution
WAYNE, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that Jesse Hall, M.D. has been appointed as Chief Medical Officer. Dr. Hall’s extensive medical and clinical development experience in areas including immunology and antibody development will be essential as he leads Aclaris’ clinical strategy to fully leverage the opportunities in the Company’s portfolio of immuno-inflammatory product candidates.
“At Aclaris, our vision is to drive the leading edge of therapeutic innovation in I&I; Jesse shares this vision and has the right experience to lead our clinical organization,” said Dr. Neal Walker, Chief Executive Officer and Chair of the Board of Directors of Aclaris. “Jesse’s diverse expertise in clinical development and operations, safety/pharmacovigilance, medical affairs, and regulatory and clinical strategy makes him the ideal leader for our clinical efforts going forward.”
“This is an exciting time to join Aclaris; they are a strong team that prioritizes good science and innovation with a deep and exciting clinical pipeline with important near-term milestones expected and ample cash resources to accomplish their goals,” said Dr. Hall. “The Company’s portfolio of potential best-in-class biologics and small molecules may help evolve clinical practice and improve the therapeutic experience of patients.”
Dr. Hall brings decades of experience to Aclaris in all phases of drug development, from early development through global regulatory filings and approvals, Phase IV post-marketing surveillance obligations, and commercial launch support. He most recently served as Chief Medical Officer for AltruBio where he was responsible for leadership of all clinical and medical functions. Prior to AltruBio, Dr. Hall served in roles of increasing responsibility at companies including Sublimity Therapeutics, Ardea Biosciences (a wholly owned subsidiary of AstraZeneca), Amgen, and Abbott Labs. He has worked on the development and launches of therapeutics including the monoclonal antibodies HUMIRA® (adalimumab) and PROLIA® (denosumab). He earned a Bachelor of Arts degree from the University of San Diego, a Doctor of Medicine degree from the University of Oklahoma College of Medicine and conducted his surgical training at the Medical College of Pennsylvania and Hahnemann University.
Notice of Issuance of Inducement Grant
In connection with the commencement of his employment, effective May 1, 2025 (the “Grant Date”), the Compensation Committee of Aclaris’ Board of Directors granted Dr. Hall nonstatutory stock options to purchase 510,000 shares of its common stock and 145,500 restricted stock units under the Aclaris Therapeutics, Inc. 2024 Inducement Plan (the “2024 Inducement Plan”). The stock options and restricted stock units were granted as inducements material to Dr. Hall becoming an employee of Aclaris in accordance with Nasdaq Listing Rule 5635(c)(4).
The 2024 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Aclaris (or following a bona fide period of non-employment), as an inducement material to such individuals’ entering into employment with Aclaris, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.
The options will have an exercise price equal to the closing price of Aclaris’ common stock on the Grant Date. Each option and restricted stock unit award will vest, and become exercisable (as applicable), as to twenty-five percent of the shares on each of the first, second, third, and fourth anniversaries of the Grant Date, subject to Dr. Hall’s continued employment with Aclaris on such vesting dates. The options and restricted stock unit awards are subject to the terms and conditions of Aclaris' 2024 Inducement Plan, and the terms and conditions of a stock option agreement or restricted stock unit award agreement, as applicable, covering the grant.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by a robust R&D engine. For additional information, please visit www.aclaristx.com and follow Aclaris on X (formerly Twitter) at @AclarisTx and on LinkedIn.
Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “anticipate,” “believe,” “expect,” “intend,” “may,” “plan,” “potential,” “will,” and similar expressions, and are based on Aclaris’ current beliefs and expectations. These forward-looking statements include expectations regarding its clinical development plans, near-term milestones, the therapeutic potential of its product candidates and the sufficiency of its cash resources to accomplish its business objectives. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, Aclaris’ reliance on third parties over which it may not always have full control, Aclaris’ ability to enter into strategic partnerships on commercially reasonable terms, the uncertainty regarding the macroeconomic environment and other risks and uncertainties that are described in the Risk Factors section of Aclaris’ Annual Report on Form 10-K for the year ended December 31, 2024, and other filings Aclaris makes with the U.S. Securities and Exchange Commission from time to time. These documents are available under the “SEC Filings” page of the “Investors” section of Aclaris’ website at www.aclaristx.com. Any forward-looking statements speak only as of the date of this press release and are based on information available to Aclaris as of the date of this release, and Aclaris assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.
Trademarks of other companies appearing in this press release are the property of their respective owners.
Aclaris Therapeutics Contact:
Will Roberts
Senior Vice President
Corporate Communications and Investor Relations
(484) 329-2125
wroberts@aclaristx.com
FAQ
Who is Jesse Hall and what is his new role at Aclaris Therapeutics (ACRS)?
What compensation package did ACRS offer to Jesse Hall in May 2025?
What is Dr. Jesse Hall's experience in pharmaceutical development?
How will Jesse Hall's appointment impact ACRS's clinical pipeline?
What are the vesting terms for Jesse Hall's ACRS stock options granted in 2025?
